4950470 Methods and compositions employing interferon-gamma
1
PATENT ABSTRACTS 305 49487~ MONOCLONAL ANTIBODIES TO GAMMA-INTERFERON, HYBRIDOMAS PRODUCING SUCH ANTIBODIES, AND KIT FOR USING SUCH ANTIBODIES Jacques Banchereau, Odile Djossou, John Wij- denes, Helgra/e/ne Cabrillat, Catherine Favre, Ecully, France assigned to Laboratoires UNICET Monoclonal antibodies to gamma-interferon and hybridomas producing such antibodies are disclosed. The antibodies are preferably of the immunoglobulin subclass IgGl, kappa, and do not bind to interferon- alpha2. least one epoxide function of an epoxy-group- containing matrix polymer, said condensation being conducted in the presence ofa bifunctional reagent which has, on one end position of a spacer unit having at least three members, an amino group capable of condensing with the al- dehyde group, and which has on the other end position a group which reacts covalently with the epoxide function. 4948877 PREPARATION OF RETROVIRUS- FREE IMMUNOGLOBULINS Gautam Mitra, Milton M Mozen assigned to Miles Laboratories Inc 4948783 ANTICARIOGENIC OR ANTIPERIDONTITIC METHOD Yasuo Kawai, Kazuoki Ishihara, Atsugi, Japan assigned to Kabushiki Kaisya Advance Kaihatsu kenkyujo An anticariogenic or antiperiodontitic agent containing, as an active component, adenosine or its derivatives having an antibacterial activity against Streptococcus mutans or Bacteroides gingivalis. This anticariogenic or anti- periodontitic agent has strong inhibitory effects on the growth of Streptococcus mutans causing dental caries and Bacteroides gingivalis causing periodontitis and has neither influence on in- testinal microflora nor any side-effects when orally administered. Immune serum globulins (ISG) can be made substantially free of infectious retroviruses by storing the ISG in a liquid state at conditions of pH, temperature and time sufficient to inactivate substantially all infectious retroviruses. Pre- ferred inactivation methods involve use of either of two specified storage conditions: (1) at a pH equal to or less than about 4.25 at a temperature of about 27 degrees C. for at least 3 days, or (2) at a pH equal to or less than about 6.8 at a tempera- ture of about 45 degrees C. for at least about 8 hours. 4950470 METHODS AND COMPOSITIONS EMPLOYING INTERFERON- GAMMA 4948836 IMMOBILIZED ANTIBODIES Beka Solomon, Eran Hadas, Gideon Fleminger, Herzellya Pituach, Israel assigned to Roehm GmbH Chemische Fabrik Antibodies which are immobilized and cova- lently bound to a matrix polymer by means of a modification in a carbohydrate region of the antibodies; wherein the binding of the antibodies is effected by condensing at least one aldehyde group in an oxidized carbohydrate region and at W Robert Fleischmann assigned to Board of Re- gents The University of Texas System The present disclosure is directed to improved pharmaceutical compositions employing interferon-gamma which have been treated to remove interferon-gamma inhibitory activity as- sociated with such preparations. In addition, the present disclosure details treatment protocols, including the elevation of patient body tempera- ture and the use of combined or sequential interferon-gamma treatments, to enhance interferon-gamma efficacy and reduce the resistance associated with interferon-alpha and/or beta therapy.
Transcript of 4950470 Methods and compositions employing interferon-gamma
PATENT ABSTRACTS 305
4 9 4 8 7 ~
M O N O C L O N A L A N T I B O D I E S T O G A M M A - I N T E R F E R O N ,
H Y B R I D O M A S P R O D U C I N G S U C H A N T I B O D I E S , A N D K I T
F O R U S I N G S U C H A N T I B O D I E S
Jacques Banchereau, Odile Djossou, John Wij- denes, Helgra/e/ne Cabrillat, Catherine Favre, Ecully, France assigned to Laboratoires UNICET
Monoclonal antibodies to gamma-interferon and hybridomas producing such antibodies are disclosed. The antibodies are preferably of the immunoglobulin subclass IgGl, kappa, and do not bind to interferon- alpha2.
least one epoxide function of an epoxy-group- containing matrix polymer, said condensation being conducted in the presence ofa bifunctional reagent which has, on one end position of a spacer unit having at least three members, an amino group capable of condensing with the al- dehyde group, and which has on the other end position a group which reacts covalently with the epoxide function.
4948877
P R E P A R A T I O N O F R E T R O V I R U S - F R E E I M M U N O G L O B U L I N S
Gautam Mitra, Milton M Mozen assigned to Miles Laboratories Inc
4948783
A N T I C A R I O G E N I C O R A N T I P E R I D O N T I T I C M E T H O D
Yasuo Kawai, Kazuoki Ishihara, Atsugi, Japan assigned to Kabushiki Kaisya Advance Kaihatsu kenkyujo
An anticariogenic or antiperiodontitic agent containing, as an active component, adenosine or its derivatives having an antibacterial activity against Streptococcus mutans or Bacteroides gingivalis. This anticariogenic or anti- periodontitic agent has strong inhibitory effects on the growth of Streptococcus mutans causing dental caries and Bacteroides gingivalis causing periodontitis and has neither influence on in- testinal microflora nor any side-effects when orally administered.
Immune serum globulins (ISG) can be made substantially free of infectious retroviruses by storing the ISG in a liquid state at conditions of pH, temperature and time sufficient to inactivate substantially all infectious retroviruses. Pre- ferred inactivation methods involve use of either of two specified storage conditions: (1) at a pH equal to or less than about 4.25 at a temperature of about 27 degrees C. for at least 3 days, or (2) at a pH equal to or less than about 6.8 at a tempera- ture of about 45 degrees C. for at least about 8 hours.
4950470
M E T H O D S A N D C O M P O S I T I O N S E M P L O Y I N G I N T E R F E R O N -
G A M M A
4948836
I M M O B I L I Z E D A N T I B O D I E S
Beka Solomon, Eran Hadas, Gideon Fleminger, Herzellya Pituach, Israel assigned to Roehm GmbH Chemische Fabrik
Antibodies which are immobilized and cova- lently bound to a matrix polymer by means of a modification in a carbohydrate region of the antibodies; wherein the binding of the antibodies is effected by condensing at least one aldehyde group in an oxidized carbohydrate region and at
W Robert Fleischmann assigned to Board of Re- gents The University of Texas System
The present disclosure is directed to improved pharmaceutical compositions employing interferon-gamma which have been treated to remove interferon-gamma inhibitory activity as- sociated with such preparations. In addition, the present disclosure details treatment protocols, including the elevation of patient body tempera- ture and the use of combined or sequential interferon-gamma treatments, to enhance interferon-gamma efficacy and reduce the resistance associated with interferon-alpha and/or beta therapy.
